Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q1 FY2022 Earnings Presentation
30 slides from Dr. Lal Pathlabs's earnings presentation, Jul 30, 2021
Slide 1: Exchange filing cover letter for earnings presentation
July 30, 2021 The National Stock Exchange of India Limited The Bombay Stock Exchange Limited Exchange Plaza, Bandra Kurla Complex, 15th Floor, Phiroze Jeejeeboy Towers Bandra (E), Mumbai - 400051 Dalal Street, Mumbai – 400001 Subject: Earnings Presentation on Unaudited Financial Results (Standalone
Slide 2: Dr. Lal PathLabs Limited Q1 FY22 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q1 FY22 Results Presentation July 30, 2021
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 4: Table of Contents
Table of Contents Dr. Lal PathLabs – At a Glance 4 Overview of Dr. Lal PathLabs 5 Key Performance Highlights 7 Financials 10 Financial Highlights 11 Operating Highlights 12 Management Commentary 13 Corporate Overview 14 Shareholding 28 Contact Us 29 DISCLAIMER: This presentation may contain ‘forward
Slide 5: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance India’s Leading & Trusted 15% 22% 200% Diagnostics Company Largest* 3 Year Revenue 3-Year PAT Equity Dividend CAGR CAGR for FY 20-21 diagnostics 70+ years of experience chain in the in the field of diagnostics country with ~86% Rs 1,153 Cr. PAN India ROCE Cash & Invest
Slide 6: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Pan-India Unique and Established integrated successful brand coverage Varied Offerings operating model 231 clinical labs Well-positioned (including National Reference Lab at Catalogue of 471 test Scalable model in one of the Established consumer Delhi and Regional panels
Slide 7: Q1 FY22 Snapshot
Q1 FY22 Snapshot 128.1% INR 606.6 Cr Revenues 101.4% 7.1 mn Patients 268.7% INR 199.0 cr Normalised EBITDA 119.3% 17.4 mn Samples 370.4% INR 133.7 cr PAT Q1 FY22 is not strictly comparable to Q1 FY21 due to nationwide lock-down in April-May 2020 and resurgent COVID-19 wave in Q1 FY22 6
Slide 8: Key Performance Highlights
Key Performance Highlights In Q1 FY22: • Revenues increased by 128% Y-o-Y to Rs. 606.6 crore • Normalised EBITDA (after eliminating the impact of stock-based compensation & CSR) stood at Rs. 199.0 crore • Profit After Tax was higher by 370%, at Rs. 133.7 crore over same period of last year Cash, FDs
Slide 9: Non-COVID, COVID & Allied Revenue
Non-COVID, COVID & Allied Revenue Rs. Cr. Total 266 432 452 431 607 374 386 336 342 206 105 74 81 74 56 11 13 43 41 1 3 11 16 6 8 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Non COVID COVID* COVID Allied 1** COVID Allied 2*** Total Covid and Covid allied contribution at 36% in Q1 FY22, 23% in Q1 FY21 *C
Slide 10: Q1 FY22 Non-COVID, COVID & Allied Revenue - Monthwise
Q1 FY22 Non-COVID, COVID & Allied Revenue - Monthwise Rs. Cr. Total 133 226 216 137 165 116 46 38 43 30 17 19 16 6 5 Apr'21 May'21 Jun'21 Non COVID COVID* COVID Allied 1** COVID Allied 2*** *COVID includes RTPCR and Antibody tests; **COVID Allied 1 includes IL-6 & D-Dimer; ***COVID Allied 2 includes
Slide 11: Financials
Financials Particulars (Rs. Cr.) Q1 FY22 Q1 FY21 Gr % FY21 Revenue 606.6 266.0 128.1% 1,581.3 Expenditure 417.6 217.6 1,145.0 EBITDA 189.0 48.4 290.6% 436.3 Stock based comp. & CSR cost 10.0 5.6 26.3 Normalised EBITDA 199.0 54.0 268.7% 462.6 Normalised Margins 32.8% 20.3% 29.3% Other Income 14.1 11.
Slide 12: Financial Highlights
Financial Highlights All figures in Rs. Crore Revenue Normalised EBITDA* PBT PAT 179.3 133.7 606.6 199.0 +370% +370% +128% +269% 266.0 38.1 54.0 28.4 Q1 FY21 Q1 FY22 Q1 FY21 Q1 FY22 Q1 FY21 Q1 FY22 Q1 FY21 Q1 FY22 *After eliminating the impact of stock based compensation, and CSR costs Finan
Slide 13: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +38 +1,552 +3,623 200 216 231 3,095 3,705 9,247 193 2,569 6,426 6,995 2,153 5,624 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 No. of Patients (Mn) No. of Samples (Mn) +43% +33% 41.8 47.7 49.7 17.6 19.4 20.3 34.
Slide 14: Management Commentary
Management Commentary Commenting on the results Commenting on the results Commenting on the results announcement, (Hony) Brig. Dr. Arvind announcement, Dr. Om Manchanda, announcement, Bharath Uppiliappan, Lal, Executive Chairman Managing Director Chief Executive Officer “India is making sustained pr
Slide 15: Corporate Overview
Corporate Overview
Slide 16: Vision, Mission & Values
Vision, Mission & Values VISION Customer First Be the most trusted healthcare partner, enabling healthier lives Ethics & Integrity VALUES Quality To be the undisputed market leader by providing accessible, affordable, timely and quality healthcare, Accountability diagnostics, applying insights and c
Slide 17: Vibrant Outlook
Vibrant Outlook Strongly develop Rest of India geographies, through Regional Reference Labs and cluster city approach for attractive markets Target to grow Evaluate best fit inorganic Deeper Penetration within the ahead opportunities in South & West North, East & Central Indian of the markets indust
Slide 18: DLPL Strategy for future growth
DLPL Strategy for future growth 1 2 Strengthen Expansion in Existing Offering Operations Expand 4 3 management of Geographic hospital based expansion and clinical laboratories 17
Slide 19: DLPL Strategy for future growth
DLPL Strategy for future growth Expand management of hospital Strengthen Existing Operations Expansion in Offering Geographic expansion based and clinical laboratories Boosting quality & reliability Improve breadth of Tap incremental contracts for Focus city & cluster approach standards diagnostic t
Slide 20: Leveraging digital to make life easier for patient
Leveraging digital to make life easier for patient Logistics Lab Operations Business Digital Lab e-Commerce Mobile app Automation Automation Continuity Plan • Self Registration • Online test / health • Test booking, view • Field Executive • Totally integrated • ‘Multi Site’ model Kiosk for patients
Slide 21: Consistent investments in R&D
Consistent investments in R&D DSIR recognized In House R&D unit R&D Collaboration with marquee Successful commercialization of with an experienced team of institutions tests research scientists and doctors Jawaharlal Nehru University for development of diagnostics kit for detection of mycobacterium
Slide 22: Genevolve: The Genomics initiative
Genevolve: The Genomics initiative GENEVOLVE brings the dawn of a new era of Genomic testing! Tests are carried out using cutting edge technologies such as Genevolve: Genomics division Next Generation Sequencing focuses on Genetic testing (NGS), MLPA, ddPCR, FISH & Sanger Sequencing among others New
Slide 23: In-house adoption of Digital Histopathology
In-house adoption of Digital Histopathology Reporting of Digital Breast cancer Panels using AI based algorithms Digital Histopathology for remote routine reporting • Enhanced access to second opinion, synchronous review of slides Opportunities • Enhanced quality of reporting created by Digital •
Slide 24: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry 100+ Quality Risk based improvement Digitally enabled Real time quality solutions control quality meetings on a assurance daily basis with implemented for monitoring quality audits framework the network partners and trainings Best in the Industry CAP Profici
Slide 25: Best in class Logistics and Supply Chain management
Best in class Logistics and Supply Chain management Real Real time time service sample monitoring tracking Control tower Real time Field Automated Cash Productivity Executive collection and route tracking process planning with clients visibility 25
Slide 26: Enhanced Customer Experience in Home Collection
Enhanced Customer Experience in Home Collection Auto Routing engine to dynamically allocate the booking to nearest Real time phlebo visibility to the patient available phlebotomist Variable model which grows with Real time slot confirmation to patient business volume ECG at home service launched in
Slide 27: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel Executive Chairman Managing Director Whole-time Director Chief Executive Officer Chief Financial Officer Shankha Banerjee Munender Soperna Rajat Kalra Manoj Garg Company Sec
Slide 28: Key Awards & Recognition
Key Awards & Recognition Dr. Om Manchanda honoured ICICI Lombard & CNBC EY Entrepreneur of The Data Quest Technology VC Circle Healthcare and awarded as ‘Healthcare TV18 India Risk Year 2019 – Life Award 2015 – Excellence Summit 2013 – Best Personality of the Year, 2020’ Management Awards 2020 Scien
Slide 29: Shareholding as of 30th June, 2021
Shareholding as of 30th June, 2021 30.0% FIIs, FPIS & Foreign Company 9.4% 55.2% Others Promoter and Promoter Group 5.4% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well 28
Slide 30: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests